Literature DB >> 1583394

A multispecies enzyme-linked immunosorbent assay for von Willebrand's factor.

R E Benson1, J L Catalfamo, W J Dodds.   

Abstract

A modified double-sandwich enzyme-linked immunosorbent assay (ELISA), which was developed for human and canine von Willebrand's factor (vWF), was adapted for quantitation of vWF in other species. In addition to human and dog plasmas, 12 other mammalian plasmas that were surveyed exhibited significant cross-species reactivity with antibodies specific for canine vWF or monoclonal antibodies against porcine or bovine vWF. Mixed combinations of monoclonal antibodies and various polyclonal antibodies were also used as sandwich or capture antibodies. The ability of this multispecies ELISA to detect less than 0.002 U of vWF per milliliter of plasma in a large number of species enhances its utility for both research and clinical diagnostic applications. A quantitative assay for rabbit vWF, which exhibits poor cross-species reactivity with most antibodies, was constructed with anti-porcine monoclonal antibody W1-5 and goat-anti-canine vWF as capture and sandwich antibodies, respectively. The same conjugate antibody configuration was used to visualize rabbit vWF multimers by immunoblotting. Specificity of the assay for vWF in human, dog, pig, and horse plasmas was confirmed by use of species-specific vWF-deficient plasmas. In other species, for which vWD plasmas were not available, ELISA specificity for vWF was demonstrated by recovery of greater than 75% of the ELISA-reactive antigen coincident with vWF multimers in the high-molecular-weight (greater than 500 kd) fractions of purified plasmas. This multispecies ELISA permits, for the first time, the measurement of vWF in a variety of mammals for which species-specific immunologic reagents do not currently exist. The results also suggest that certain vWF epitopes have been highly conserved among phylogenetically diverse species.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583394

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

2.  Vascular lesions and s-thrombomodulin concentrations from auricular arteries of rabbits infused with microbubble contrast agent and exposed to pulsed ultrasound.

Authors:  James F Zachary; James P Blue; Rita J Miller; William D O'Brien
Journal:  Ultrasound Med Biol       Date:  2006-11       Impact factor: 2.998

3.  Immune complex formation after xenotransplantation : evidence of type III as well as type II immune reactions provide clues to pathophysiology.

Authors:  Z E Holzknecht; S Coombes; B A Blocher; T B Plummer; M Bustos; C L Lau; R D Davis; J L Platt
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.

Authors:  Margaret V Ragni; Enrico M Novelli; Anila Murshed; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

5.  Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.

Authors:  Qin Wang; Douglas Shorten; Xin Xu; Gray D Shaw; Robert G Schaub; Christopher Shea; Jonathan Brooks; Dianne Sako; Erin Wiswall; Jin Xu; Pamela Szklut; Vikram S Patel
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

6.  Validated sandwich ELISA for the quantification of von Willebrand factor in rabbit plasma.

Authors:  Brendon W Smith; Jana Strakova; Jennifer L King; John W Erdman; William D O'Brien
Journal:  Biomark Insights       Date:  2010-11-28

7.  Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

Authors:  C D Porada; C Sanada; C R Long; J A Wood; J Desai; N Frederick; L Millsap; C Bormann; S L Menges; C Hanna; G Flores-Foxworth; T Shin; M E Westhusin; W Liu; H Glimp; E D Zanjani; J N Lozier; V Pliska; G Stranzinger; H Joerg; D C Kraemer; G Almeida-Porada
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

8.  A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.

Authors:  M V Ragni; R C Jankowitz; H L Chapman; E P Merricks; M T Kloos; A M Dillow; T C Nichols
Journal:  Haemophilia       Date:  2008-08-01       Impact factor: 4.287

9.  Clotting factor VIII (FVIII) and thrombin generation in camel plasma: A comparative study with humans.

Authors:  Abdel Galil M Abdel Gader; Abdul Karim M Al Momen; Abdulqader Alhaider; Marjory B Brooks; James L Catalfamo; Ahmed A Al Haidary; Mansour F Hussain
Journal:  Can J Vet Res       Date:  2013-04       Impact factor: 1.310

10.  Constitutional flavonoids derived from Epimedium dose-dependently reduce incidence of steroid-associated osteonecrosis not via direct action by themselves on potential cellular targets.

Authors:  Ge Zhang; Xin-Luan Wang; Hui Sheng; Xin-Hui Xie; Yi-Xin He; Xin-Sheng Yao; Zi-Rong Li; Kwong-Man Lee; Wei He; Kwok-Sui Leung; Ling Qin
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.